Comparative Pharmacology
Head-to-head clinical analysis: CYCLAPEN W versus NALLPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAPEN W versus NALLPEN.
CYCLAPEN-W vs NALLPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
NALLPEN (naloxone) is a competitive opioid receptor antagonist that binds to mu, kappa, and delta opioid receptors, reversing the effects of opioid agonists including respiratory depression, sedation, and hypotension.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
1 gram IV every 8 hours over 30 minutes.
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
Terminal elimination half-life is 2.0-3.0 hours; prolonged in renal impairment (up to 24 hours).
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Primarily renal excretion (80-90% unchanged) with minor biliary/fecal elimination (5-10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic